Recombinant HIV-1 Envelope Protein for Vaccine Use

In pursuit of an effective vaccine to end the global HIV-1/AIDS pandemic, researchers at the Vaccine Research Center ( “VRC”) continue to study the structure of HIV-1. Recently, these researchers have determined the three-dimensional structure of the HIV-1 Envelope trimeric ectodomain (“Env”), comprised of three gp120 and three gp41 subunits, in its prefusion, mature, closed conformation.The researchers hypothesize that immunization with the prefusion, closed HIV-1 Env protein will elicit a neutralizing immune response. The VRC researchers engineered a portion of the HIV-1 Env trimer to stabilize it in this closed conformation for use as an immunogen.This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404, as well as for further development and evaluation under a research collaboration.IC: NIAIDNIH Ref. No.: E-178-2014-0Advantages: Currently, no licensed HIV-1 vaccine exists.Applications: Vaccine for prevention of HIV-1 infection.Therapeutic vaccine for treatment of HIV-1 infection.Provider Technology ID: 3338Updated On: Oct 18, 2018Date Published: Thursday, October 18, 2018Patent Application: 62/046,05962/136,480PCT/US2015/04872915/508,88516/557,894Patent Authority: USUSPCTUSUSLead Inventor: Inventor IC: NIAIDNIAIDNIAIDNIAIDNIAIDNIAIDNIAIDNIAIDNIAIDNIAIDNIAIDNIAIDNIAIDNIAIDNIAIDNIAIDNIAIDInventor Lab URL: http://irp.nih.gov/pi/peter-kwongh...

Source: NIH OTT Licensing Opportunities - October 18, 2018 Category: Research Authors: ajoyprabhu3 Source Type: research